×
About 60,235 results

High Risk of Long COVID Neurologic Sequelae in Veterans
https://www.mdedge.com/fedprac/article/258374/long-covid/high-risk-long-covid-neurologic-sequelae-veterans
Jan Dyer

Oct 3rd, 2022 - We now know that the effects of COVID-19 don’t always end when the infection seems over. Long COVID—the postacute sequelae—can encompass a wide range of extrapulmonary organ dysfunctions.

Psychiatric Risks Subside Before Neurologic Risks After COVID-19
https://www.pulmonologyadvisor.com/general-medicine/neurological-psychiatric-outcomes-covid-19-risks-last-longer/
Pulmonology Advisor

Oct 3rd, 2022 - Following COVID-19 infection, the risk for developing neurological disorders remains high after 2 years, while the risk for psychiatric disorders subsides earlier. These are the findings of a study published in Lancet Psychiatry. Researchers analyzed outcome data in a multinational, retrospective cohort study. They obtained data from the TriNetX electronic health records network between January...

ACR Updates Guidelines for Glucocorticoid-Induced Osteoporosis
https://www.clinicaladvisor.com/home/topics/rheumatology-information-center/acr-updates-guidelines-for-prevention-and-treatment-of-glucocorticoid-induced-osteoporosis/
Clinical Advisor

Oct 3rd, 2022 - The American College of Rheumatology (ACR) updated their 2017 ACR guidelines for preventing and treating glucocorticoid-induced osteoporosis (GIOP). The full manuscript will be published in Arthritis & Rheumatology and Arthritis Care and Research in early 2023. Since the publication of the 2017 ACR guidelines for GIOP, treatments, including abaloparatide (PTHrP) and romosozumab, have been avail...

High Procedural Success With Novel LAA Occluder for Preventing Stroke in AF
https://www.thecardiologyadvisor.com/home/topics/interventional/high-procedural-success-with-novel-laa-occluder-for-preventing-stroke-in-atrial-fibrillation-af/
Cardiology Advisor

Oct 3rd, 2022 - Left atrial appendage (LAA) closure with use of a novel, disc-like occluder (the Leftear device [Pulse Scientific]) has demonstrated a high rate of procedural success, and satisfactory safety and efficacy for stroke prevention among patients with nonvalvular atrial fibrillation (NVAF). These findings were published in the journal JACC: Asia. Researchers sought to explore the effectiveness and s...

Intracranial Atherosclerotic Disease Clinical Practice Guidelines (ESO, 2022)
https://www.medscape.com/viewarticle/981521

Oct 3rd, 2022 - Guidelines for the management of patients with intracranial atherosclerotic disease (ICAD) were published in September 2022 by the European Stroke Organisation (ESO) in European Stroke Journal.[1] Oral anticoagulation is not recommended over aspirin in patients with an ischemic stroke or transient ischemic attack due to high-grade stenosis related to intracranial atherosclerotic disease (ICAD)....

OAC in Patients With AF and COVID-19 Lowers Rates of Death, Thrombotic Events
https://www.pulmonologyadvisor.com/general-medicine/oral-anticoagulation-oac-in-patients-with-atrial-fibrillation-af-and-covid-19-lowers-rates-of-death-thrombotic-events/
Pulmonology Advisor

Sep 30th, 2022 - In patients with baseline atrial fibrillation (AF) who are hospitalized with COVID-19, individuals who are receiving preadmission oral anticoagulation (OAC) have lower rates of death, as well as arterial and venous thrombotic events, and have less severe SARS-CoV-2 infection. These findings were published in the The American Journal of Cardiology. A retrospective cohort study was conducted amon...

Focus on Cardiometabolic Disease Risk in Psoriatic Arthritis – With Brittany Weber, MD
https://www.rheumatologyadvisor.com/home/topics/psoriatic-arthritis/focus-on-cardiometabolic-disease-risk-in-psoriatic-arthritis-with-brittany-weber-md/
Rheumatology Advisor

Sep 30th, 2022 - Patients with vs without psoriatic arthritis (PsA) have markedly elevated risks to their cardiometabolic health. More than half of patients with PsA have at least 1 comorbidity (Figure 1).1 Patients with PsA are estimated to be 46% more likely to be diagnosed with a cardiovascular disease (CVD) than the general population, with a higher rate of hospitalization related to CVD as well.2 Moreover,...

Neurological vs Psychiatric Outcomes After COVID-19: Which Risks Last Longer?
https://www.dermatologyadvisor.com/home/topics/general-medicine/neurological-psychiatric-outcomes-covid-19-risks-last-longer/
Dermatology Advisor

Sep 30th, 2022 - Following COVID-19 infection, the risk for developing neurological disorders remains high after 2 years, while the risk for psychiatric disorders subsides earlier. These are the findings of a study published in Lancet Psychiatry. Researchers analyzed outcome data in a multinational, retrospective cohort study. They obtained data from the TriNetX electronic health records network between January...

SMART-CHOICE 3-Year Results Support Dropping Aspirin After PCI
https://www.medscape.com/viewarticle/981741

Sep 30th, 2022 - Shortening the duration of dual antiplatelet therapy (DAPT) and continuing with a P2Y12 inhibitor alone after percutaneous coronary intervention (PCI) was associated with a similar rate of ischemic events but with less bleeding than prolonged DAPT after 3 years of follow-up in the SMART-CHOICE trial. "The current results of extended follow-up from the SMART-CHOICE trial support evidence of an a...

Golden State Medical Supply, Inc. Issues a Voluntary Nationwide Recall of Atenolol 25 m...
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/golden-state-medical-supply-inc-issues-voluntary-nationwide-recall-atenolol-25-mg-tablets-and
MedWatch; FDA

Sep 29th, 2022 - FOR IMMEDIATE RELEASE- SEPTEMBER 29, 2022, Golden State Medical Supply, Incorporated (GSMS, Inc.) - Camarillo, CA has initiated a voluntary recall of the products listed in the table below because a report was received that a bottle containing Clopidogrel 75mg Tablets produced with lot# GS046745 was mislabeled as Atenolol 25mg Tablets. This voluntary recall only affects products with lot# GS046...

ACR Updates Guidelines for Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
https://www.endocrinologyadvisor.com/home/topics/bone-metabolism/acr-updates-guidelines-for-prevention-and-treatment-of-glucocorticoid-induced-osteoporosis/
Endocrinology Advisor

Sep 29th, 2022 - The American College of Rheumatology (ACR) updated their 2017 ACR guidelines for preventing and treating glucocorticoid-induced osteoporosis (GIOP). The full manuscript will be published in Arthritis & Rheumatology and Arthritis Care and Research in early 2023. Since the publication of the 2017 ACR guidelines for GIOP, treatments, including abaloparatide (PTHrP) and romosozumab, have been avail...

Potential Risk Factors Identified in “Long COVID”
https://www.rheumatologyadvisor.com/general-medicine/long-covid-risk-factors-assessed-with-documented-care/
Rheumatology Advisor

Sep 29th, 2022 - Factors associated with an increased risk for long COVID include older age, a higher comorbidity burden, disease severity at the time of diagnosis, and unvaccinated status at initial onset of infection. These study findings were published in JAMA Network Open. Using data from the Veterans Affairs Corporate Data Warehouse and the COVID-19 Shared Data Resource, researchers conducted a retrospecti...

Do Older vs Younger Docs Treat Atrial Fibrillation Differently?
https://www.medscape.com/viewarticle/979415

Sep 29th, 2022 - This transcript has been edited for clarity. Robert A. Harrington, MD: Hi. I'm Bob Harrington from Stanford University. I'm here in Barcelona at the European Society of Cardiology (ESC) meeting. First, I have to say, wow, it's fantastic to be back at a live, face-to-face meeting, getting to see friends and colleagues from around the globe in addition to hearing about great science. While here, ...

Women Earn Less From Drug, Device Firms; New Rules on Nondrug Cancer Pain Therapy; and Coffee Cuts Cardio Illness
https://www.medscape.com/viewarticle/981544

Sep 29th, 2022 - Women Earn Less From Drug, Device Firms Female physicians earn far less in compensation from drug and medical device companies than do their male peers, new research shows. In fact, the gender-based pay disparity widened from 2013 to 2019, according to a study published in JAMA Surgery by faculty from the University of California and Weill Cornell Medicine surgery departments. The study analyze...

Alopecia Areata: Positive Results Reported for Two Investigational JAK Inhibitors
https://www.medscape.com/viewarticle/981622

Sep 29th, 2022 - Treatment with deuruxolitinib and ritlecitinib, two investigational Janus kinase (JAK) inhibitors, resulted in substantial regrowth of scalp hair for patients with alopecia areata (AA) in separate studies reported at the European Academy of Dermatology and Venereology (EADV) 2022 Annual Meeting. In the THRIVE-AA1 study, the primary endpoint of a Severity of Alopecia Tool (SALT) score of ≤20 ― w...

Food Insecurity a Growing Problem for Many With CVD
https://www.medscape.com/viewarticle/981642

Sep 29th, 2022 - A growing number of Americans with cardiovascular disease (CVD) have limited or uncertain access to food, results of a new study suggest. An analysis of data from the National Health and Nutrition Examination Survey (NHANES) representing more than 300 million American adults found that, overall, 38.1% of people with cardiovascular disease were food insecure in 2017-2019. Twenty years earlier, t...

PROACT Xa Trial of Apixaban With On-X Heart Valve Stopped
https://www.medscape.com/viewarticle/981644

Sep 29th, 2022 - Artivion Inc. has halted the PROACT Xa clinical trial that was testing whether patients with an On-X mechanical aortic valve could be safely and effectively managed with the direct oral anticoagulant (DOAC) apixaban (Eliquis) rather than warfarin. The decision to stop the trial was based on the recommendation of the independent data and safety monitoring board (DSMB), which cited a lack of evid...

National Institutes of Health Awards Cleveland Clinic $10.7 Million to expand national consortium studying Dementia with Lewy Bodies
https://www.eurekalert.org/news-releases/966417

Sep 29th, 2022 - The National Institutes of Health (NIH) awarded a $10.7 million five-year renewal grant to Cleveland Clinic to expand a national research consortium focused on improving the diagnosis and treatments for Dementia with Lewy Bodies. The Dementia with Lewy Bodies Consortium, established in 2017, centralized research efforts and created a national, coordinated registry for clinical data. September 2...

One Win, One Near Miss for Calcium Modification Before PCI
https://www.medscape.com/viewarticle/981559

Sep 28th, 2022 - Two small studies offer mixed results using vastly different approaches to modify severely calcified lesions before percutaneous coronary intervention (PCI). In the open-label COPS trial, use of a cutting balloon inflated at high pressure resulted in greater minimal stent area (MSA) and more symmetric stent expansion at the calcium site than standard noncompliant balloon angioplasty. Although a...

Positive Topline Phase 3 Data for Lecanemab in Early Alzheimer's
https://www.medscape.com/viewarticle/981579

Sep 28th, 2022 - Lecanemab (Eisai/Biogen), an investigational amyloid-clearing monoclonal antibody, reduced cognitive decline by 27% compared to placebo and decreased amyloid levels in the brain of adults enrolled in a phase 3 trial. The Clarity AD trial included 1795 adults with early AD and confirmed amyloid pathology in the brain. Treatment consisted of lecanemab 10 mg/kg biweekly or matching placebo. Treatm...